Journal of the American College of Surgeons · 2009 · 24 citations · 22 references
MedicineCancer BiologyOncologyMetastasisNeoplasiaTumor MicroenvironmentLocal InvasionLymph Node MetastasisLymphatic MetastasisMalignant NeoplasmsMetastatic DisseminationSentinel Lymph Node BiopsyAxillary Sentinel Lymph Node BiopsyMelanoma Metastasis To Lymph NodesSentinel Lymph Node MetastasisSentinel Lymph Node StagingSentinel Lymph Node Status
BACKGROUND: How to best risk-stratify patients with metastatic melanoma in the sentinel node (SN) is controversial. Not all node-positive disease is equivalent in terms of disease-free or overall survival, and some have suggested that submicrometastatic disease, characterized by <0.1 mm tumor burden, can represent a distinct classification not associated with a chance for recurrence or death. We hypothesize that all patients with metastatic melanoma cells in the sentinel node have potentially life-threatening disease. STUDY DESIGN: This is a retrospective review of an IRB-approved, prospectively maintained melanoma database of >1,100 patients. All invasive melanoma patients who had an SN biopsy and at least 1 year of followup were included. Patients with metastatic melanoma in the SN were divided into groups according to diameter of SN tumor burden: node-negative, <0.1 mm (submicrometastatic), 0.1 to 1.0 mm, and >1.0 mm. Statistical methods included the Jonckheere-Terpstra method, Fisher's exact tests, and Kaplan-Meier method. RESULTS: From July 1, 1998 to July 1, 2007, 578 patients with invasive melanoma underwent SN procedure. Median followup was 2.2 years. There was a statistically significant difference in the proportion of patients who experienced a recurrence between the node-negative group (11%) and the <0.1 mm group (24%) (p = 0.049). Patients in the submicrometastatic group have a statistically significant (p = 0.048) earlier recurrence than those in the node-negative group. CONCLUSIONS: These results suggest that patients with submicrometastatic SN disease should not be treated as node-negative, as it appears to represent a more biologically aggressive melanoma, associated with a substantially faster time to recurrence. We cannot agree with recent proposals that patients with very small tumor burden in the SN can be treated as node-negative and be spared completion node dissection.
22
Sentinel-Node Biopsy or Nodal Observation in Melanoma
Donald L. Morton, John F. Thompson, Alistair J. Cochran et al. · New England Journal of Medicine · 2006 · 1.8K citations · Full text
International Union against Cancer
Journal of the Faculty of Radiologists · 1959 · 1.2K citations
The Orderly Progression of Melanoma Nodal Metastases
Douglas S. Reintgen, C. Wayne Cruse, Karen Wells et al. · Annals of Surgery · 1994 · 741 citations
Sentinel Node Biopsy for Early-Stage Melanoma
Donald L. Morton, Alistair J. Cochran, John F. Thompson et al. · Annals of Surgery · 2005 · 718 citations · Full text